{"denoms":[{"counts":[{"groupId":"BG000","value":"395"},{"groupId":"BG001","value":"399"},{"groupId":"BG002","value":"794"}],"units":"Participants"}],"groups":[{"description":"Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.","id":"BG000","title":"Arm A (ABVD)"},{"description":"Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide \\[375 mg/m²\\] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.","id":"BG001","title":"Arm B (Stanford V)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18","upperLimit":"83","value":"33"},{"groupId":"BG001","lowerLimit":"16","upperLimit":"83","value":"33"},{"groupId":"BG002","lowerLimit":"16","upperLimit":"83","value":"33"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"369"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"425"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"96"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"349"},{"groupId":"BG001","value":"349"},{"groupId":"BG002","value":"698"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Eligible patients are included in the primary analysis."}